LeonaBio (LONA) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LeonaBio (LONA) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 56.1% versus a loss of 62.6%. LeonaBio is the larger company by market cap ($26.4 million vs $21.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LONA | MGX |
|---|---|---|
| Share price | $2.02 | $0.565 |
| Market cap | $26.41M | $21.36M |
| 1-day change | -17.89% | -7.95% |
| YTD return | -73.32% | -65.12% |
| 1-year return | -56.13% | -62.58% |
| 5-year return | -98.55% | — |
| EPS (TTM) | $-22.20 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $25.21M |
| Revenue growth (YoY) | — | -51.79% |
| Net income (latest FY) | $-105.61M | $-87.87M |
| Operating margin | — | -380.85% |
| Net margin | — | -348.54% |
| 52-week high | $14.21 | $1.87 |
| 52-week low | $1.91 | $0.562 |
| Distance from 52-week high | -85.78% | -69.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +757.92% | +1138.94% |
| Average volume | 195.37K | 163.21K |
| Shares outstanding | 13.08M | 37.81M |
| Employees | 19 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
LONA vs MGX FAQ
Which is bigger, LeonaBio or Metagenomi Therapeutics?
LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $21.36M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, LONA or MGX?
LONA returned -56.13% over the past 12 months, compared with -62.58% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are LeonaBio and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.